Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.
RECRUITINGOBSERVATIONAL

The Norwegian Immunotherapy in Multiple Myeloma Study

The Norwegian Immunotherapy in Multiple Myeloma Study - A Population-based Longitudinal Observational Multicenter Study on Effectiveness and Complications of Immunotherapy in Multiple Myeloma in the Norwegian Myeloma Cohort

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

The goal of this observational study is to study the effectiveness and complications of novel immunotherapies used in the treatment of multiple myeloma in routine care in Norway. The aim is to close knowledge gaps, generate evidence for future clinical trials and contribute to future consensus on how to monitor for adverse events, and what mitigation strategies should be implemented, so that we can increase patient survival and quality-of-life.

Who May Be Eligible (Plain English)

Inclusion criteria - Participants age ≥ 18 years - Prior diagnosis of one of the following - Multiple myeloma as defined according to IMWG criteria - Primary plasma cell leukemia as defined according to IMWG consensus definition - AL-amyloidosis as defined according to IMWG criteria - Planned treatment with one of the following outside clinical trials (list to be amended based on approvals within the EU): - Teclistamab (Tecvayli) - Elranatamab (Elrexfio) - Talquetamab (Talvey) - Idecabtagene vicleucel (ide-cel/Abecma) - Ciltacabtagene autoleucel (cilta-cel/Carvykti) Who Should NOT Join This Trial: - None Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion criteria * Participants age ≥ 18 years * Prior diagnosis of one of the following * Multiple myeloma as defined according to IMWG criteria * Primary plasma cell leukemia as defined according to IMWG consensus definition * AL-amyloidosis as defined according to IMWG criteria * Planned treatment with one of the following outside clinical trials (list to be amended based on approvals within the EU): * Teclistamab (Tecvayli) * Elranatamab (Elrexfio) * Talquetamab (Talvey) * Idecabtagene vicleucel (ide-cel/Abecma) * Ciltacabtagene autoleucel (cilta-cel/Carvykti) Exclusion Criteria: * None

Treatments Being Tested

DRUG

Teclistamab

Real-world use and dosing

DRUG

Elranatamab

Real-world use and dosing

BIOLOGICAL

Ciltacabtagene Autoleucel

Real-world use.

DRUG

Talquetamab

Real-world use and dosing

BIOLOGICAL

Idecabtagene vicleucel

Real-world use and dosing

Locations (20)

Sørlandet Hospital - Arendal
Arendal, Norway
Ålesund hospital, Department of hematology
Ålesund, Norway
Haukeland University Hospital
Bergen, Norway
Bodø Hospital
Bodø, Norway
Bærum Hospital
Bærum, Norway
Drammen hospital
Drammen, Norway
Førde hospital
Førde, Norway
Innlandet hospital trust
Gjøvik, Norway
Haugesund hospital
Haugesund, Norway
Sørlandet hospital
Kristiansand, Norway
Nordmøre and Romsdal Hospital - Kristiansund
Kristiansund, Norway
Levanger hospital
Levanger, Norway
Nordmøre and Romsdal Hospital - Molde
Molde, Norway
Akershus University Hospital (AHUS)
Nordbyhagen, Norway
Diakonhjemmet hospital
Oslo, Norway
Lovisenberg Diaconal Hospital
Oslo, Norway
Oslo Myeloma Center, Oslo University Hospital
Oslo, Norway
Telemark Hospital Trust
Skien, Norway
Stavanger University hospital
Stavanger, Norway
University hospital of North Norway
Tromsø, Norway